News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mirus Bio LLC Release: the First Dedicated Breast Cancer Cell Line Transfection Reagent



4/4/2013 9:22:47 AM

MADISON, Wis., April 3, 2013 /PRNewswire/ -- Mirus Bio has expanded its transfection expertise with the development of the TransIT-BrCa Transfection Reagent a high performance, low toxicity, DNA transfection reagent specifically formulated for breast cancer cell types. This new reagent offers users:

  • Superior DNA DeliveryAchieve high expression levels in breast cancer cell types including: MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, T47D.
  • Formulated for Low Cellular ToxicityMaintain cell density and reduce experimental biases due to toxicity.
  • Scientifically ProvenDeveloped by Mirus Bio scientists with nearly 2 decades of gene delivery expertise.

(Logo: http://photos.prnewswire.com/prnh/20100818/CG52502LOGO)

Mirus Bio is dedicated to advancing breast cancer research. In addition to providing scientists with state-of-the-art transfection reagents Mirus will donate a portion of every sale of TransIT-BrCa Transfection Reagent to the Breast Cancer Research Foundation.

Visit www.mirusbio.com for all your transfection needs including data, protocols, technical support or to place an order.

About Mirus Bio LLC

ONE FOCUS: TRANSFECTION
Every transfection product offered by Mirus Bio is the result of scientific discovery and development from an in-house team of organic chemists, molecular biologists, cell biologists and biochemists. Almost two decades after its founding, transfection continues to be the focal point and passion of Mirus, giving researchers the most reliable products and expertise.

SOURCE Mirus Bio LLC


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES